期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

5-羟色胺受体拮抗剂在肺动脉高压防治中的应用与展望 被引量：1

Application and prospects of 5-HT receptor antagonists in the prevention and treatment of pulmonary hypertension
下载PDF
导出
摘要 肺动脉高压是一组由多种病因和发病机制引起的以肺血管阻力进行性增加为特征的病理生理综合征。临床表现为右心室功能不全,预后不良,严重者可发生右心衰竭而死亡。本文主要综述了5-羟色胺与肺动脉高压的关系及5-羟色胺受体拮抗剂在肺动脉高压防治中的作用,展望了5-羟色胺受体拮抗剂可能是一类有潜力的新型治疗肺动脉高压的药物。 Pulmonary hypertension is a group of clinical pathophysiological syndrome characterized by increased pulmonary vascular resistance due to multiple etiologies and pathogenesis.The main clinical manifestations are right ventricular dysfunction with poor prognosis,and patient of severe right heart failure can even cause death.This article reviews the relationship between the 5-HT and pulmonary hypertension,and the 5-HT receptor antagonists＇ effects on the prevention and treatment of pulmonary hypertension.The article also prospects that 5-HT receptor antagonists may be a kind of very promising new drugs in the treatment of pulmonary hypertension.
作者 肖雄 侯颖 李小强
机构地区 第四军医大学药学系药理学教研室
出处 《中国临床药理学与治疗学》 CAS CSCD 2011年第1期111-115,共5页 Chinese Journal of Clinical Pharmacology and Therapeutics
基金 国家自然科学基金(30800433)
关键词 5-羟色胺 5-羟色胺受体 拮抗剂 肺动脉高压 5-hydroxytryptamine 5-hydroxytryptamine receptor Antagonist Pulmonary artery hypertension
分类号 R543.2 [医药卫生—心血管疾病]
  • 相关文献

参考文献31

  • 1王虹,解卫平,汪海,胡刚.盐酸埃他卡林对内皮素1诱导的大鼠肺动脉高压的影响[J].中国临床药理学与治疗学,2005,10(1):9-14. 被引量：10
  • 2McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, Ameri can Thoracic Society, Inc. , and the Pulmonary Hypertension Association [J]. Circulation, 2009, 119 (16) :2250-2294.
  • 3Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the Euro pean Society of Cardiology (ESC) and the European Respiratory Soci'ety (ERS), endorsed by the Inter national Society of Heart and Lung Transplantation (ISHLT) [J]. Eur Heart J, 2009, 30(20):2493-2537.
  • 4Liu C, Liu K, Ji Z, et al. Treatments for pulmona ry arterial hypertension[J]. Respir Med, 2006, 100 (5) :765-774.
  • 5Dwyer N, Kilpatrick D. Bosentan for the treatment of adult pulmonary hypertension[J]. Future Cardiol, 2011,7(1):19-37.
  • 6Chan SY, Losealzo J. Pathogenic mechanisms of pulmonary arterial hypertension[J]. J Mol Cell Cardiol, 2008, 44(1) :14-30.
  • 7Nebigil CG, Etienne N, Schaerlinger B, et al. Developmentally regulated serotonin 5-HT2B receptors [J]. Int J Dev Neurosci, 2001, 19(4):365-372.
  • 8Lederer DJ, Horn EM, Rosenzweig EB, et al.Plasma serotonin levels are normal in pulmonary ar terial hypertension [J]. Pulm Pharmacol Ther, 2008, 21(1):112-114.
  • 9Kereveur A, Callebert J, Humbert M, et al. High plasma serotonin levels in primary pulmonary hyper tension. Effect of long-term epoprostenol (prosta cyclin) therapy[J]. Arterioscler Thromb Vasc Biol, 2000, 20(10):2233-2239.
  • 10Lam DD, Przydzial MJ, Ridley SH, et al. Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 recep tors[J]. Endocrinology, 2008, 149 (3): 1323-1328.

二级参考文献12

  • 1Michel RP, Langleben D, Dupuis J. The endothelin system in pulmonary hypertension[ J]. Can J Physiol Pharmacol, 2003; 81:542 - 54
  • 2Wort SJ, Wood M, Warner TD, Evans TW, Mitchell JA. Endogenously released endohtelin-1 from human pulmonary artery smooth muscle promotes cellular proliferation[ J]. Am J Respir Cell Mol Biol,2001 ;25:104- 10
  • 3Sato K, Morio Y, Morris KG, Rodman DM, McMurtry IF.Mechanism of hypoxic pulmonary vasoconstriction involves ET (A) receptor-mediated inhibition of K(ATP) channel[J]. Am J Physiol Lung Cell Mol Physiol, 2000; 278: L434 - 42
  • 4Brayden JE. Functional roles of KATP channels in vascular smooth muscles[ J]. Clin Exp Pharmacol Physiol, 2002; 29: 312-6
  • 5Cole W C, Clement-Chomienne O. ATP-sensitive K+ channels of vascular smooth muscle cells [ J]. J Cardiovasc Electrophysiol,2003;14:94- 103
  • 6vWang H. Pharmacological characteristics of the novel antihypertensive drug, iptakalim hydrochloride and its molecular mechanisms[J]. Drug Dev Res,2003; 58:65 - 8
  • 7Higenbottam TW, Laude EA. Endothelial dysfunction providing the basis for the treatment of pulmonary hypertension [ J ].Chest, 1998; 114:72 - 8
  • 8Tilton RG, Munsch CL, Sherwood SJ, Chen YF, Wu C, et al.Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist[ J ]. Pulm Pharmacol Ther,2000; 13: 87 - 97
  • 9Watanuki M, Horie M, Tsuchiya K, Obayashi K, Sasayama S.Endothelin-1 inhibition of cardiac ATP-sensitive K+ channels via pertussin-toxin-sensitive G-proteins [ J ]. Cardiovasc Res, 1997;33:123 - 30
  • 10Cui Y, Tran S, Tinker A, Clapp LH. The molecular composition of KATP channels in human pulmonary artery smooth muscle cells and their modulation by growth[ J]. Am J Respir Cell Mol Biol,2002;26:135 - 43

共引文献9

同被引文献15

引证文献1

二级引证文献11

中国临床药理学与治疗学
2011年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部